Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-490 in relapsed or refractory non-Hodgkin lymphoma (Phase I/IIa, open-label)
CTR20250606Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Mar 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ICP-490 in non-Hodgkin lymphoma (NHL), sponsored by Innovent Biologics. Started Mar 2025; status: active.
02
Drugs
ICP-490
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20250606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250606.